- Home
- IRMD vs SYRE Comparison
IRMD vs SYRE Comparison
Compare IRMD & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- SYRE
- Stock Information
- Founded
- IRMD 1992
- SYRE 2013
- Country
- IRMD United States
- SYRE United States
- Employees
- IRMD N/A
- SYRE N/A
- Industry
- IRMD Medical/Dental Instruments
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- SYRE Health Care
- Exchange
- IRMD Nasdaq
- SYRE Nasdaq
- Market Cap
- IRMD 756.5M
- SYRE 841.4M
- IPO Year
- IRMD 2014
- SYRE 2016
- Fundamental
- Price
- IRMD $56.32
- SYRE $17.79
- Analyst Decision
- IRMD Strong Buy
- SYRE Buy
- Analyst Count
- IRMD 1
- SYRE 5
- Target Price
- IRMD $72.00
- SYRE $55.00
- AVG Volume (30 Days)
- IRMD 54.1K
- SYRE 591.7K
- Earning Date
- IRMD 08-04-2025
- SYRE 08-06-2025
- Dividend Yield
- IRMD 1.21%
- SYRE N/A
- EPS Growth
- IRMD 10.72
- SYRE N/A
- EPS
- IRMD 1.55
- SYRE N/A
- Revenue
- IRMD $75,154,639.00
- SYRE N/A
- Revenue This Year
- IRMD $10.62
- SYRE N/A
- Revenue Next Year
- IRMD $9.69
- SYRE N/A
- P/E Ratio
- IRMD $36.23
- SYRE N/A
- Revenue Growth
- IRMD 11.04
- SYRE N/A
- 52 Week Low
- IRMD $42.34
- SYRE $10.91
- 52 Week High
- IRMD $63.29
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- IRMD 40.34
- SYRE 61.20
- Support Level
- IRMD $55.77
- SYRE $16.16
- Resistance Level
- IRMD $57.36
- SYRE $18.31
- Average True Range (ATR)
- IRMD 1.45
- SYRE 0.96
- MACD
- IRMD -0.37
- SYRE 0.20
- Stochastic Oscillator
- IRMD 21.09
- SYRE 84.18
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.